Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Tiziano Barbui, Alessandra Iurlo et al.|Blood Cancer Journal|2018Cited by 38
Prevalence of the C536T Mutation in the Tissue Factor Pathway Inhibitor (TFPI) Gene among Patients with Venous Thromboembolic DiseaseElena Rossi, Katia Paciaroni, Mario Bazzan et al.|Thrombosis and Haemostasis|2001Cited by 10